Modified ibogaine fragments: Synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5,6-hexahydroazepino[4,5- b]benzothiophenes

Journal of Medicinal Chemistry

Volumn 41, Issue 23, 1998, Pages 4486-4491

  Efange, Simon M N ^a,c   Mash, Deborah C ^b   Khare, Anil B ^a   Ouyang, Quinjie ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 3 ETHYL 5 (3 BROMOPHENYL) 1,2,3,4,5,6 HEXAHYDROAZEPINO[4,5 B]BENZOTHIOPHENE; 3 ETHYL 5 (3 NITROPHENYL) 1,2,3,4,5,6 HEXAHYDROAZEPINO[4,5 B]BENZOTHIOPHENE; 3 ETHYL 5 (3,4 DICHLOROPHENYL) 1,2,3,4,5,6 HEXAHYDROAZEPINO[4,5 B]BENZOTHIOPHENE; 3 ETHYL 5 PHENYL 1,2,3,4,5,6 HEXAHYDROAZEPINO[4,5 B]BENZOTHIOPHENE; 3 METHYL 5 PHENYL 1,2,3,4,5,6 HEXAHYDROAZEPINO[4,5 B]INDOLE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID ISOPROPYL ESTER; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; BUTACLAMOL; COCAINE; DIZOCILPINE; DOPAMINE RECEPTOR; EMONAPRIDE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; HALOPERIDOL; IBOGAINE; INDOLE DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALOXONE; NORIBOGAINE; OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; DOPAMINERGIC SYSTEM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; MOUSE; NONHUMAN; PSYCHOPHARMACOLOGY; TRADITIONAL MEDICINE;

ANIMALS; BRAIN; CARRIER PROTEINS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; EXCITATORY AMINO ACID ANTAGONISTS; HALLUCINOGENS; HUMANS; IBOGAINE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; THIOPHENES;

EID: 0032487930     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980156y     Document Type: Article

References (56)

1. Schneider, J. A.; Sigg, E. B. Neuropharmacological studies on ibogaine, an indole alkaloid with central stimulant properties. Ann. N.Y. Acad. Sci. 1957, 66, 765-776.
2. Barabe, P. Religion of Eboga or the Bwiti of the Fangs. Méd. Trop. 1982, 42, 251-257.
3. Dybowski, J.; Landrin, E. Sur l'iboga, sur ses propriétés excitantes, sa composition et sur l'alcaloïde nouveau qui renferme. Compt. Rend. 1901, 133, 748.
4. Haller, A.; Heckel, E. Sur l'iboga, principe actif d'une plante du genre Tabernanaemontana, originaire du Congo. Compt. Rend. 1901, 133, 850.
5. Lotsof, H. S. Rapid method for interrupting the narcotic addiction syndrome. U.S. Patent No. 4,499,096, 1985.
6. Lotsof, H. S. Rapid method for interrupting the cocaine and amphetamine abuse syndrome. U.S. Patent No. 4,587,243, 1986.
7. Kaplan, C. D.; Ketzer, E.; De Jong, J.; De Vries, M. Reaching a stage of wellness: multistage explorations in social neuroscience. Soc. Neurosci. Bull. 1993, 6, 6-7.
8. Sisko, B. Interrupting drug dependency with ibogaine: a summary of four case histories. Multidisciplin. Assoc. Psychedel. Studies 1993, IV, 15-24.
9. Touchette, N. Ibogaine neurotoxicity raises new questions in addiction research. J. NIH Res. 1993, 5, 50-55.
10. Glick, S.D.; Rossman, K.; Steindorf, S.; Maisonneuve, I. M.; Carlson, J. N. Effects and aftereffects of ibogaine on morphine self-administration in rats. Eur. J. Pharmacol. 1991, 195 (3), 341-345.
11. Glick, S. D.; Kuehne, M. E.; Raucci, J.; Wilson, T. E. Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects On dopamine release in nucleus accumbens and striatum. Brain Res. 1994, 657, 14-22.
12. Maisonneuve, I. M.; Rossman, K. L.; Keller, R. W., Jr.; Glick, S. D. Acute and prolonged effects of Ibogaine on brain dopamine metabolism and morphine induced-locomotor activity in rats. Brain Res. 1992, 575 (1), 69-73.
13. Pearl, S. M.; Johnson, D. W.; Glick, S. D. Prior morphine exposure enhances ibogaine antagonism of morphine-induced locomotor stimulation. Psychopharmacology 1995, 121, 470-475.
14. Dzoljic, E. D.; Kaplan, C. D.; Dzoljic, M. R. Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats. Arch. Inter. Pharmacodyn. 1988, 294, 64-70.
15. Glick, S. D.; Rossman, K.; Rao, N. C.; Maisonneuve, I. M.; Carlson, J. N. Effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor. Neuropharmacology 1992, 31, 497-500.
16. Aceto, M. D.; Bowman, E. R.; Harris, L. S. Dependence studies of new compounds in the rhesus monkey, rat and mouse. NIDA Res. Monogr. 1990, 95, 578.
17. Sershen, H.; Hashim, A.; Lajtha, A. Ibogaine reduces preference for cocaine consumption in C57BL/6By mice. Pharmacol. Biochem. Behav. 1994, 47, 13-19.
18. Cappendijk, S. L. T.; Dzoljic, M. R. Inhibitory effects of ibogaine on cocaine self-administration in rats. Eur J. Pharmacol. 1993, 241 (2-3), 261-265.
19. Sershen, H.; Hashim, A.; Harsing, L.; Lajtha, A. Ibogaine antagonizes cocaine-induced locomotor stimulation in mice. Life Sci. 1992, 50, 1079-1086.
20. Rezvani, A. H.; Overstreet, D. H.; Lee, Y.-W. Attenuation of alcohol intake by ibogaine in three strains of alcohol-preferring rats. Pharmacol. Biochem. Behav. 1995, 52, 615-620.
21. Benwell, M. E.; Holtom, P. E.; Moran, R. J.; Balfour, D. J. Neurochemical and behavioral interactions between ibogaine and nicotine in the rat. Br. J. Pharmacol. 1996, 117, 743-749.
22. Maisonneuve, I. M.; Mann, G. L.; Deibel, C. R.; Click, S. D. Ibogaine and the dopamine response to nicotine. Psychopharmacology 1997, 129, 249-256.
23. Repke, D. B.; Artis, D. R.; Nelson, J. T.; Wong, E. H. F. Abbreviated Ibogaine congeners. Synthesis and Reactions of Tropan-3-yl-2- and 3-indoles. Investigation of an Unusual isomerization of 2-substituted Indoles Using Computational and Spectroscopic Techniques. J. Org. Chem. 1994, 59, 2164-2171.
24. Hester, J. B.; Tang, A. H.; Keasling, H. H.; Veldkamp, W. Azepinoindoles, I. Hexahydroazepinol[4,5-b]indoles. J. Med. Chem. 1968, 11, 101-106.
25. Gallant, D. M.; Bishop, M. P.; Bishop, G.; O'Meallie, L. A controlled evaluation in chronic schizophrenic patients. Curr. Ther. Res. 1967, 9, 579-580.
26. Itil, T. M.; Stock, M. J.; Duffy, A. D.; Esquerazi, A.; Salenty, D.; Han, T. H. Therapeutic trials and EKG investigations with SCH12679 in behaviorally disturbed adolescents. Curr. Ther. Res. 1972, 14, 136-150.
27. Albert, J. M.; Elie, R.; Cooper, S. F.; Clermont, A.; Langlois, Y. Efficacy of SCH12679 in the management of aggressive mental retardates. Curr. Ther. Res. 1977, 21, 786-795.
28. Elie, R.; Langlois, Y.; Cooper, S. F.; Ravel, G.; Albert, J. M. Comparison of SCH12679 and thioridazine in aggressive mental retardates. Can. J. Psychiat. 1980, 25, 484-491.
29. Elliot, A. J.; Gold, E. H.; Guzik, H. Synthesis of Some 5-phenylhexahydroazepino[4,5-6]indoles as potential neuroleptic agents. J. Med. Chem. 1980, 23, 1268-1269.
30. Mash, D. C.; Staley, J. K.; Baumann, M. H.; Rothman, R. B.; Hearn, W. L. Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Sci. 1995, 57, PL45-50.
31. Deecher, D. C.; Teitler, M.; Soderlund, D. M.; Bornmann, W. G.; Kuehne, M. E.; Glick, S. D. Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies. Brain Res. 1992, 571 (2), 242-247.
32. Staley, J. K.; Ouyang, Q.; Pablo, J.; Hearn, W. L.; Flynn, D. D.; Rothman, R. B.; Rice, K. C.; Mash, D. C. Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine. Psychopharmacology 1996, 127, 10-18.
33. Glick, S. D.; Maisonneuve, I. M.; Pearl, S. M. Evidence for roles of kappa-opioid and NMDA receptors in the mechanism of action of ibogaine. Brain Res. 1997, 749, 340-343.
34. Codd, E. E. High affinity ibogaine binding to a mu opioid agonist site. Life Sci. 1995, 57, PL315-320.
35. Mash, D. C.; Staley, J. K.; Pablo, J. P.; Holohean, A. M.; Hackman, J. C.; Davidoff, R. A. Properties of ibogaine and its principal metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex. Neurosci. Lett. 1995, 192, 53-56.
36. 3H]MK-801 binding to the NMDA receptor complex. Psychopharmacology 1994, 114, 672-674.
37. Popik, P.; Layer, R. T.; Fossom, L. H.; Benveniste, M.; Geter-Douglass, B.; Witkin, J. M.; Skolnick, P. NMDA antagonist properties of the putative anti-addictive drug, ibogaine. J. Pharmacol. Exp. Ther. 1995, 275, 753-760.
38. 3H]dopamine. Brain Res. Bull. 1996, 40, 63-67.
39. Chen, K.; Kokate, T. G.; Donevan, S. D.; Carroll, F. I.; Rogawski, M. A. Ibogaine blockade of the NMDA receptor: in vitro and in vivo studies. Neuropharmacology 1996, 35, 423-431.
40. Layer, R. T.; Skolnick, P.; Bertha, C. M.; Bandarage, U. K.; Kuehne, M. E.; Popik, P. Structurally modified ibogaine analogues exhibit differing affinities for NMDA receptors. Eur. J. Pharmacol. 1996, 309, 159-165.
41. Whitaker, P. M.; Seeman, P. Hallucinogen binding to dopamine/ neuroleptic receptors. J. Pharm. Pharmacol. 1977, 29, 506-507.
42. Bowen, W. D.; Vilner, B. J.; Williams, W.; Bertha, C. M.; Kuehne, M. E.; Jacobson, A. E. Ibogaine and its congeners are σ2 receptor-selective ligands with moderate affinity. Eur. J. Pharmacol. 1995, 279, R1-3.
43. Mach, R. H.; Smith, C. R.; Childers, S. R. Ibogaine possesses a selective affinity for σ2 receptors. Life Sci. 1995, 57, PL57-62.
44. Schneider, A. S.; Nagel, J. E.; Mah, S. J. Ibogaine selectively inhibits nicotinic receptor-mediated catecholamine release. Eur. J. Pharmacol. 1996, 317, R1-2.
45. Badio, B.; Padgett, W. L.; Daly, J. W. Ibogaine: a potent noncompetitive blocker of ganglionic/neuronal nicotonic receptors. Mol. Pharmacol. 1997, 57, 1-5.
46. Nelson, J. L.; Keyser, G. E. Synthesis of fluorescent nucleotide analogues: 5′-mono-, di-, and triphosphates of linear-benzoguanosine, linear-benzoinosine, and linear-benzoxanthosine. Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 4262-4264.
47. 1-dopamine receptors. J. Pharmacol. Exp. Ther. 1990, 252, 558-567.
48. DeKeyser, J.; Walraevens, H.; Ebinger, G.; Vauquelin, G. In human brain two subtypes of D1 receptors can be distinguished on the basis of differences in guanine nucleotide effect on agonist binding. J. Neurochem. 1989, 53, 1096-1102.
49. Jarvie, K. R.; Niznik, H. B.; Seeman, P. Dopamine D-2 receptors in canine brain: ionic effects on [3H]neuroleptic binding. Eur. J. Pharmacol. 1987, 114, 163-171.
50. 125I](R)-trans-7-hydroxy-2-[N-propyl-N-(3′-iodo- 2′propenyl)-amino]tetralin binding to dopamine D3 receptors in rat olfactory tubercle. J. Pharmacol. Exp. Ther. 1994, 268, 935-942.
51. 125I]RTI-121. Synapse 1995, 21, 364-372.
52. 3H]U-69593 binding sites in rat brain: evidence for k opioid receptor subtypes. Eur. J. Pharmacol. 1988, 154, 27-34.
53. Rothman, R. B.; Xu, H.; Wang, J. B.; Partilla, J. S.; Kayakiri, H.; Rice, K. C.; Uhl, G. R. Ligand selectivity of cloned human and rat opiod mu receptors. Synapse 1995, 21, 60-64,
54. 125I]RTI-55: In vitro binding and autoradiographic characterization. J. Neurochem. 1994, 62, 549-556.
55. 35S]GTPγS binding. NeuroReport 1998, 9, 109-114.
56. Andersen, P. H.; Gronvald, F. C.; Hohlweg, R.; Hansen, L. B.; Guddal, E.; Baestrup, C.; Nielsen, E. B. NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists. Eur. J. Pharmacol. 1992, 219, 45-52.